Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan-Mar;13(1):68-72.
doi: 10.4103/aer.AER_192_18.

Postoperative Nausea and Vomiting Prophylaxis: A Comparative Study of Ramosetron and Palonosetron in Patients Undergoing Laparoscopic Cholecystectomy - A Prospective Randomized Trial

G Sowmya Reddy  1 , B Manjusruthi  1 , G Jyothsna  1
Affiliations

Postoperative Nausea and Vomiting Prophylaxis: A Comparative Study of Ramosetron and Palonosetron in Patients Undergoing Laparoscopic Cholecystectomy - A Prospective Randomized Trial

G Sowmya Reddy et al. Anesth Essays Res. 2019 Jan-Mar.

Abstract

Background: In spite of the availability of several antiemetic drugs, postoperative nausea and vomiting (PONV) is very common following laparoscopic surgery. Selective 5-hydroxytryptamine type 3 receptor antagonists are considered first-line agents for prophylaxis for PONV.

Aims: In this study, we investigated and compared the efficacy of ramosetron and palonosetron in preventing PONV following laparoscopic cholecystectomy.

Statistical analysis: The data were analyzed with Student's t-test and Chi-square test.

Settings and design: This was a randomized, prospective, double-blinded, observational clinical study.

Methods: A total number of 80 patients, undergoing elective laparoscopic cholecystectomy surgeries under general anesthesia, were randomly assigned to one of the two equal groups to receive either of the following: Group R - received injection ramosetron 0.3 mg and Group P - received injection palonosetron 0.075 mg intravenous bolus immediately before the induction of anesthesia. The incidence of PONV, adverse effects of the study drugs, and need for rescue antiemetics were recorded over the next 48 h. Primary outcome was the incidence of PONV. Secondary outcomes were adverse effects of the study drugs and need for rescue.

Statistical analysis: The data were analyzed with Student's t-test and Chi-square test.

Results: The incidence of a complete response (no PONV and no rescue medication) during 0-3 h in the postoperative period was 82.5% with ramosetron and 90% with palonosetron; the incidence during 3-24 h postoperatively was 80% with ramosetron and 87.5% with palonosetron. During 24-48 h, the incidence was 65% and 90%, respectively (P < 0.05). The incidences of adverse effects were statistically insignificant between the groups.

Conclusion: Prophylactic therapy with palonosetron is more effective than ramosetron for long-term prevention of PONV following laparoscopic cholecystectomy.

Keywords: Antiemetics; ondansetron; palonosetron; postoperative nausea and vomiting.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Consort diagram showing the number of patients included and analyzed
See this image and copyright information in PMC

References

    1. Kapur PA. The big “little problem”. Anesth Analg. 1991;73:243–5. - PubMed
    1. Agarkar S, Chatterjee AS. Comparison of ramosetron with ondansetron for the prevention of post-operative nausea and vomiting in high-risk patients. Indian J Anaesth. 2015;59:222–7. - PMC - PubMed
    1. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118:85–113. - PubMed
    1. Salmenperä M, Kuoppamäki R, Salmenperä A. Do anticholinergic agents affect the occurrence of postanaesthetic nausea? Acta Anaesthesiol Scand. 1992;36:445–8. - PubMed
    1. Islan S, Jain PN. PONV: A review article. Indian J Anaesth. 2004;48:253–8.